Moderna Stock Rises as Flu Vaccine Approval Offers Spark for a Post-Pandemic Future

Moderna's mRNA-based flu vaccine, mFlusiva, is approved by the Food and Drug Administration for adults aged 50 and over.

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。